3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Genitourinary
1
Conditions
Carcinoma, Renal Cell
77
Kidney Neoplasms
23
Prostatic Neoplasms
22
Neoplasm Metastasis
13
Colorectal Neoplasms
10
Neoplasms
8
Melanoma
7
Carcinoma, Transitional Cell
6
Breast Neoplasms
6
Urinary Bladder Neoplasms
5
Stomach Neoplasms
5
Glioblastoma
5
Carcinoma, Non-Small-Cell Lung
5
Pancreatic Neoplasms
4
Ovarian Neoplasms
4
Carcinoma, Hepatocellular
4
Uterine Cervical Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
3
Sarcoma
3
Urologic Neoplasms
2
Triple Negative Breast Neoplasms
2
Myeloproliferative Disorders
2
Multiple Myeloma
2
Hereditary leiomyomatosis and renal cell cancer
2
Hematologic Neoplasms
2
Financial Stress
2
Esophageal Neoplasms
2
Endometrial Neoplasms
2
Colonic Neoplasms
2
Cholangiocarcinoma
2
Interventions
padeliporfin
5
Nivolumab
5
Ipilimumab
4
Sunitinib
3
Specimen Handling
3
Mitomycin
3
Magnetic Resonance Spectroscopy
3
Gemcitabine
3
Abiraterone Acetate
3
pembrolizumab
2
motexafin gadolinium
2
enfortumab vedotin
2
darolutamide
2
cabozantinib
2
abiraterone
2
Surveys and Questionnaires
2
Radiation Dose Hypofractionation
2
Pluvicto
2
Paclitaxel
2
Cisplatin
2
Carboplatin
2
CTLA-4 Antigen
2
vinflunine
1
valrubicin
1
tislelizumab
1
temsirolimus
1
sipuleucel-T
1
relatlimab
1
palladium-bacteriopheophorbide
1
palbociclib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Urogenital Neoplasms
×
Bevacizumab
×
Genitourinary
×
Clear all
NCT00631371
2016-04-27
INTORACT
Pfizer
Phase 3
Completed
791 enrolled
11 charts